Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genix PharmaceuticalsGENPF 3-Year EBITDA Growth Rate is 27.90% as of Apr. 2026. The stock has 3 warning signs investors should review. Among 807 Drug Manufacturers companies, Genix Pharmaceuticals ranks better than 76.83% on this metric.
During the past 12 months, Genix Pharmaceuticals's average EBITDA Per Share Growth Rate was -300.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Genix Pharmaceuticals was 58.50% per year. The lowest was -166.80% per year. And the median was -5.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Genix Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
GENPF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genix Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Genix Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.90% mean?
Genix Pharmaceuticals (GENPF) has a 3-Year EBITDA Growth Rate of 27.90% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Genix Pharmaceuticals and its competitors. According to the industry distribution chart, Genix Pharmaceuticals ranks #187 out of 807 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is Genix Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Genix Pharmaceuticals' current 3-Year EBITDA Growth Rate is 27.90%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Genix Pharmaceuticals' value of 27.90% is 213.5% above this industry median. Based on the distribution chart, Genix Pharmaceuticals ranks #187 out of 807 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Genix Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #187 out of 807 companies for 3-Year EBITDA Growth Rate. This places Genix Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Genix Pharmaceuticals' value of 27.90% is 213.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genix Pharmaceuticals's current 3-Year EBITDA Growth Rate of 27.90% is 213.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current 3-Year EBITDA Growth Rate is 27.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current 3-Year EBITDA Growth Rate of 27.90%. The current 3-Year EBITDA Growth Rate is 27.90% and 213.5% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current 3-Year EBITDA Growth Rate is 27.90% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENPF has been successfully added to your 
